keyword
https://read.qxmd.com/read/38592653/elution-behavior-of-drugs-in-high-speed-counter-current-chromatography-using-on-column-complexation-with-metal-ions
#1
JOURNAL ARTICLE
Yukiko Moriiwa, Atsushi Shoji, Yoichi Shibusawa, Akio Yanagida
In this study, determination of (nitrogen containing) drugs by on-column complexation with metal ions in high-speed counter-current chromatography (HSCCC) was investigated. Bromazepam (BMP) was strongly retained in the organic upper stationary phase (UP) of the two-phase solvent system composed of tert-butyl methyl ether-acetonitrile-water (2:2:3, v/v/v) by eluting the aqueous lower mobile phase (LP) at a flow rate of 2 mL min-1 . On the other hand, BMP (200 µg mL-1 ) was eluted faster without retention to the organic UP with the two-phase system containing 100 μg mL-1 of copper ions (CuCl2 ) because a very polar BMP-Cu2+ complex was immediately formed in the aqueous LP...
April 9, 2024: Analytical Sciences: the International Journal of the Japan Society for Analytical Chemistry
https://read.qxmd.com/read/38581325/the-clinical-efficacy-of-combining-ambroxol-hydrochloride-with-antibiotics-for-the-treatment-of-chronic-bronchitis
#2
JOURNAL ARTICLE
Min Li, Jialin Bao, Li Yang
OBJECTIVE: To evaluate the clinical efficacy and impact on pulmonary function of ambroxol hydrochloride combined with antibiotics in the treatment of chronic bronchitis. METHODS: This randomized controlled trial involved the enrollment and randomization of 98 CB patients admitted to Anting Hospital from January 2020 to January 2021, with participants divided into an observation group and a control group at a 1:1 ratio, comprising 49 cases in each group. The control group received cefmetazole alone, whereas the observation group received ambroxol hydrochloride combined with antibiotics...
April 5, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38553911/rapid-and-long-lasting-efficacy-of-high-dose-ambroxol-therapy-for-neuronopathic-gaucher-disease-a-case-report-and-literature-review
#3
REVIEW
Kanako Higashi, Yuri Sonoda, Noriyuki Kaku, Fumihiko Fujii, Fumiya Yamashita, Sooyoung Lee, Vlad Tocan, Go Ebihara, Wakato Matsuoka, Kenichi Tetsuhara, Motoshi Sonoda, Pin Fee Chong, Yuichi Mushimoto, Kanako Kojima-Ishii, Masataka Ishimura, Yuhki Koga, Atsuhisa Fukuta, Nana Akagi Tsuchihashi, Yoshikazu Kikuchi, Takahito Karashima, Takaaki Sawada, Taeko Hotta, Makoto Yoshimitsu, Hideyuki Terazono, Tatsuro Tajiri, Takashi Nakagawa, Yasunari Sakai, Kimitoshi Nakamura, Shouichi Ohga
Gaucher disease (GD) is a lysosomal storage disorder caused by a deficiency in the GBA1-encoded enzyme, β-glucocerebrosidase. Enzyme replacement therapy is ineffective for neuronopathic Gaucher disease (nGD). High-dose ambroxol has been administered as an alternative treatment for a group of patients with nGD. However, little is known about the clinical indication and the long-term outcome of patients after ambroxol therapy. We herein report a case of a female patient who presented with a progressive disease of GD type 2 from 11 months of age and had the pathogenic variants of p...
April 2024: Molecular Genetics & Genomic Medicine
https://read.qxmd.com/read/38550092/retracted-study-on-the-efficacy-and-safety-of-ambroxol-combined-with-methylprednisolone-in-patients-with-acute-lung-injury
#4
BioMed Research International
[This retracts the article DOI: 10.1155/2021/5771101.].
2024: BioMed Research International
https://read.qxmd.com/read/38526267/ambroxol-the-cough-expectorant-with-neuroprotective-effects
#5
JOURNAL ARTICLE
Kristin Patzwaldt, Salvador Castaneda-Vega
No abstract text is available yet for this article.
November 1, 2024: Neural Regeneration Research
https://read.qxmd.com/read/38501299/two-green-and-sensitive-spectrofluorimetric-approaches-for-determination-of-ambroxol-and-guaifenesin-in-their-single-and-combined-pharmaceutical-formulations
#6
JOURNAL ARTICLE
Ghidaa G Elawadi, Fawzi Elsebaei, Mona E Fathy, Mohammed E-S Metwally
Ambroxol hydrochloride (AMX) and guaifenesin (GFN) are approved drugs utilized to treat coughs through their potent mucolytic and expectorant properties. Due to their massive, combined administration in many illnesses, there is a persistent need for their concurrent estimation in different pharmaceutical formulations. Two sensitive, environmentally friendly spectrofluorimetric methods were developed. AMX was determined using the first method (I) without interference from GFN. This method depends on the quenching of Erythrosine B (EB) native fluorescence at 552 nm after excitation at 527 nm due to the formation of a non-fluorescent AMX-EB ion-pair complex in Britton-Robinson buffer (BRB) solution pH (3...
March 2024: Luminescence: the Journal of Biological and Chemical Luminescence
https://read.qxmd.com/read/38445786/risk-of-major-birth-defects-after-first-trimester-exposure-to-carbocisteine-and-ambroxol-a-multicenter-prospective-cohort-study-using-counseling-data-for-drug-safety-during-pregnancy
#7
JOURNAL ARTICLE
Mariko Usuda, Seung Chik Jwa, Mikako Goto, Mizuki Kobayashi, Hiroyuki Nagano, Naho Yakuwa, Ritsuko Yamane, Atsuko Murashima, Hideki Makabe
To assess the risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol during pregnancy, we conducted a prospective cohort study using counseling data for drug use during pregnancy provided by the Japan Drug Information Institute in Pregnancy and Toranomon Hospital. Counseling information, including drug usage and participants' demographic information, was collected between April 1988 and December 2017. Pregnancy outcome data, including major birth defects, were obtained using a questionnaire administered 1 month after delivery...
March 6, 2024: Congenital Anomalies
https://read.qxmd.com/read/38436193/clinical-pharmacist-intervention-in-contraindications-of-the-co-administration-of-cefoperazone-and-ambroxol-hydrochloride-injection
#8
JOURNAL ARTICLE
Z-Q Du, Y Jiang, R-R Lu, Q Zhou, H-H Zhu, Y Shen
BACKGROUND: Clinical pharmacists identified contraindications in two cases concerning the co-administration of cefoperazone and ambroxol hydrochloride injection, prompting a thorough investigation. CASE PRESENTATION: Clinically, two cases of contraindications for the co-administration of cefoperazone and ambroxol hydrochloride injection were discovered. After the intervention and analysis by clinical pharmacists, the possible reason could be the precipitation of free alkali due to the immediate administration of ambroxol after the infusion of cefoperazone...
February 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38414738/exploring-the-efficacy-and-safety-of-ambroxol-in-gaucher-disease-an-overview-of-clinical-studies
#9
REVIEW
Feda E Mohamed, Fatma Al-Jasmi
Gaucher disease (GD) is mainly caused by glucocerebrosidase (GCase) enzyme deficiency due to genetic variations in the GBA1 gene leading to the toxic accumulation of sphingolipids in various organs, which causes symptoms such as anemia, thrombocytopenia, hepatosplenomegaly, and neurological manifestations. GD is clinically classified into the non-neuronopathic type 1, and the acute and chronic neuronopathic forms, types 2 and 3, respectively. In addition to the current approved GD medications, the repurposing of Ambroxol (ABX) has emerged as a prospective enzyme enhancement therapy option showing its potential to enhance mutated GCase activity and reduce glucosylceramide accumulation in GD-affected tissues of different GBA1 genotypes...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38406552/the-use-of-ambroxol-for-the-treatment-of-gaucher-disease-a-systematic-review
#10
REVIEW
Diego Agustín Abelleyra Lastoria, Simranjeet Grewal, Derralynn Hughes
Gaucher disease (GD) is a heterogeneous condition requiring tailored treatment approaches. The aim of this systematic review was to synthesise and evaluate current evidence pertaining to the use of Ambroxol for the treatment of GD. Published and unpublished literature databases, conference proceedings and the reference lists of included studies were searched until 23 November 2023. A narrative synthesis was performed. Database search and risk of bias assessment were performed independently by two reviewers...
February 2024: EJHaem
https://read.qxmd.com/read/38333295/insights-into-the-management-of-lewy-body-dementia-a-scoping-review
#11
REVIEW
Sajjad Ahmed Khan, Sadab Khan, Huma Kausar, Rajat Shah, Anish Luitel, Sakshyam Gautam, Surya Bahadur Parajuli, Vivek K Rauniyar, Moien A B Khan
Lewy body dementia (LBD) is situated at the convergence of neurodegenerative disorders, posing an intricate and diverse clinical dilemma. The accumulation of abnormal protein in the brain, namely, the Lewy body causes disturbances in typical neural functioning, leading to a range of cognitive, motor, and mental symptoms that have a substantial influence on the overall well-being and quality of life of affected individuals. There is no definitive cure for the disease; however, several nonpharmacological and pharmacological modalities have been tried with questionable efficacies...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38188862/predicting-delirium-and-the-effects-of-medications-in-hospitalized-covid-19-patients-using-machine-learning-a-retrospective-study-within-the-korean-multidisciplinary-cohort-for-delirium-prevention-komcode
#12
JOURNAL ARTICLE
So Hee Lee, Hyun Jung Hur, Sung Nyun Kim, Jang Ho Ahn, Du Hyun Ro, Arum Hong, Hye Yoon Park, Pyoeng Gyun Choe, Back Kim, Hye Youn Park
OBJECTIVE: Delirium is commonly reported from the inpatients with Coronavirus disease 2019 (COVID-19) infection. As delirium is closely associated with adverse clinical outcomes, prediction and prevention of delirium is critical. We developed a machine learning (ML) model to predict delirium in hospitalized patients with COVID-19 and to identify modifiable factors to prevent delirium. METHODS: The data set (n = 878) from four medical centers was constructed...
2024: Digital Health
https://read.qxmd.com/read/38087032/the-combination-of-astragalus-injection-and-ambroxol-hydrochloride-in-the-adjuvant-treatment-of-copd-a-systematic-review-and-meta-analysis
#13
JOURNAL ARTICLE
Zubing Zhou, Lele Yang, Chao Hu, Rui Gao, Xiaobo Zhang, Tao Shen
Chronic obstructive pulmonary disease (COPD) is a severe condition that leads to premature mortality and places a significant financial burden on healthcare systems. An adjunctive therapy in COPD includes the simultaneous administration of astragalus injection and ambroxol hydrochloride. Despite its widespread use, the effectiveness of this combined approach in COPD treatment has not been systematically evaluated. Thus, we conducted a systematic review and meta-analysis to assess the efficacy of combining astragalus injection with ambroxol hydrochloride as an adjuvant treatment for COPD...
December 12, 2023: Scientific Reports
https://read.qxmd.com/read/38069298/ambroxol-enhanced-frequency-and-amplitude-of-beating-cilia-controlled-by-a-voltage-gated-ca-2-channel-cav1-2-via-ph-i-increase-and-cl-i-decrease-in-the-lung-airway-epithelial-cells-of-mice
#14
JOURNAL ARTICLE
Takashi Nakahari, Chihiro Suzuki, Kotoku Kawaguchi, Shigekuni Hosogi, Saori Tanaka, Shinji Asano, Toshio Inui, Yoshinori Marunaka
Ambroxol (ABX), a frequently prescribed secretolytic agent which enhances the ciliary beat frequency (CBF) and ciliary bend angle (CBA, an index of amplitude) by 30%, activates a voltage-dependent Ca2+ channel (CaV 1.2) and a small transient Ca2+ release in the ciliated lung airway epithelial cells (c-LAECs) of mice. The activation of CaV 1.2 alone enhanced the CBF and CBA by 20%, mediated by a pHi increasei and a [Cl- ]i decrease in the c-LAECs. The increase in pHi , which was induced by the activation of the Na+ -HCO3 - cotransporter (NBC), enhanced the CBF (by 30%) and CBA (by 15-20%), and a decrease in [Cl- ]i , which was induced by the Cl- release via anoctamine 1 (ANO1), enhanced the CBA (by 10-15%)...
November 30, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38027469/ambroxol-as-a-disease-modifying-treatment-to-reduce-the-risk-of-cognitive-impairment-in-gba-associated-parkinson-s-disease-a-multicentre-randomised-double-blind-placebo-controlled-phase-ii-trial-the-ambitious-study-protocol
#15
JOURNAL ARTICLE
Fabiana Colucci, Micol Avenali, Rosita De Micco, Marco Fusar Poli, Silvia Cerri, Mario Stanziano, Ana Bacila, Giada Cuconato, Valentina Franco, Diego Franciotta, Cristina Ghezzi, Matteo Gastaldi, Antonio Emanuele Elia, Luigi Romito, Grazia Devigili, Valentina Leta, Barbara Garavaglia, Nico Golfrè Andreasi, Federico Cazzaniga, Chiara Reale, Caterina Galandra, Giancarlo Germani, Pierfrancesco Mitrotti, Gerardo Ongari, Ilaria Palmieri, Marta Picascia, Anna Pichiecchio, Mattia Verri, Fabrizio Esposito, Mario Cirillo, Federica Di Nardo, Simone Aloisio, Mattia Siciliano, Sara Prioni, Paolo Amami, Sylvie Piacentini, Maria Grazia Bruzzone, Marina Grisoli, Fabio Moda, Roberto Eleopra, Alessandro Tessitore, Enza Maria Valente, Roberto Cilia
BACKGROUND: Heterozygous mutations in the GBA gene, encoding the lysosomal enzyme β-glucocerebrosidase (GCase), are the most frequent genetic risk factor for Parkinson's disease (PD). GBA -related PD (GBA-PD) patients have higher risk of dementia and reduced survival than non-carriers. Preclinical studies and one open-label trial in humans demonstrated that the chaperone ambroxol (ABX) increases GCase levels and modulates α-synuclein levels in the blood and cerebrospinal fluid (CSF)...
2023: BMJ neurology open
https://read.qxmd.com/read/38013123/development-and-characterization-of-a-spray-dried-inhalable-ternary-combination-for-the-treatment-of-pseudomonas-aeruginosa-biofilm-infection-in-cystic-fibrosis
#16
JOURNAL ARTICLE
Nasser Alhajj, Mohd Fakharul Zaman Raja Yahya, Niall J O'Reilly, Helen Cathcart
Cystic fibrosis (CF) is an inherited lung disease characterised by the accumulation of thick layers of dried mucus in the lungs which serve as a nidus for chronic infection. Pseudomonas aeruginosa is the predominant cause of chronic lung infection in cystic fibrosis. The dense mucus coupled with biofilm formation hinder antibiotic penetration and prevent them from reaching their target. Mucoactive agents are recommended in the treatment of CF in combination with antibiotics. In spite of the extensive research in developing novel drug combinations for the treatment of lung infection in CF, to our knowledge, there is no study that combines antibiotic, antibiofilm and mucoactive agent in a single inhaled dry powder formulation...
November 25, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/37954384/meta-analysis-of-the-efficacy-of-budesonide-and-ambroxol-hydrochloride-inhalation-in-children-with-pneumonia-and-their-effects-on-inflammatory-response
#17
JOURNAL ARTICLE
Huanan Shen, Xingni Zhao, Liangyin Xu
Childhood pneumonia, often caused by acute upper respiratory tract infections or bronchitis, is one of the leading causes of mortality in children. Nebulized inhalation, as a low-risk treatment method, has garnered significant attention. However, its effectiveness and safety remain controversial. In this study, a systematic review of relevant literature on the use of budesonide (BUD) and ambroxol hydrochloride (AMB) inhalation in the treatment of childhood pneumonia was conducted, and a total of 10 articles were included...
November 2023: Heliyon
https://read.qxmd.com/read/37924136/therapeutic-potential-of-lianhua-qingke-in-airway-mucus-hypersecretion-of-acute-exacerbation-of-chronic-obstructive-pulmonary-disease
#18
JOURNAL ARTICLE
Yuanjie Hao, Tongxing Wang, Yunlong Hou, Xiaoqi Wang, Yujie Yin, Yi Liu, Ningxin Han, Yan Ma, Zhen Li, Yaru Wei, Wei Feng, Zhenhua Jia, Hui Qi
BACKGROUND: Lianhua Qingke (LHQK) is an effective traditional Chinese medicine used for treating acute tracheobronchitis. In this study, we evaluated the effectiveness of LHQK in managing airway mucus hypersecretion in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD). METHODS: The AECOPD model was established by subjecting male Wistar rats to 12 weeks of cigarette smoke (CS) exposure (80 cigarettes/day, 5 days/week for 12 weeks) and intratracheal lipopolysaccharide (LPS) exposure (200 μg, on days 1, 14, and 84)...
November 3, 2023: Chinese Medicine
https://read.qxmd.com/read/37915234/acute-generalized-exanthematous-pustulosis-induced-by-ambroxol-confirmed-by-positive-skin-tests
#19
Batoule Mahrous, Gwendy Dupire, Eloise Anthony, Benoit Ben-Said
No abstract text is available yet for this article.
November 1, 2023: Contact Dermatitis
https://read.qxmd.com/read/37901900/association-between-ambroxol-at-the-usual-dose-and-the-risk-of-parkinson-s-disease-in-chronic-lung-disease
#20
JOURNAL ARTICLE
Min Seung Kim, Jungkuk Lee, Dongwoo Kang, Hasung Kim, Suk Yun Kang
No abstract text is available yet for this article.
November 2023: Journal of Clinical Neurology
keyword
keyword
82635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.